Michael Cecchini, MD
Associate Professor of Medicine (Medical Oncology)Cards
About
Research
Overview
Medical Research Interests
DNA Repair; Gastrointestinal Neoplasms; Immunotherapy
Publications
2024
Epidemiology, treatment and outcomes of gastroenteropancreatic neuroendocrine neoplasms
Uhlig J, Nie J, Gibson J, Cecchini M, Stein S, Lacy J, Kunz P, Kim H. Epidemiology, treatment and outcomes of gastroenteropancreatic neuroendocrine neoplasms. Scientific Reports 2024, 14: 30536. PMID: 39690170, PMCID: PMC11652651, DOI: 10.1038/s41598-024-81518-4.Peer-Reviewed Original ResearchConceptsGEP-NEN patientsGastroenteropancreatic neuroendocrine neoplasmsOverall survivalGEP-NENsTreatment patternsSystemic therapyNeuroendocrine neoplasmsAssociated with improved survivalLow-grade diseaseNational Cancer DatabaseLonger overall survivalSite-specific incidenceDisease specific factorsG3 NENSurgical resectionCancer DatabaseImproved survivalLow-stageCox regressionImprove outcomesPatientsIncidence increasesInternational guidelinesInvestigate incidenceSurvivalMolecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations
Yasin F, Sokol E, Vasan N, Pavlick D, Huang R, Pelletier M, Levy M, Pusztai L, Lacy J, Zhang J, Ross J, Cecchini M. Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations. The Oncologist 2024, 29: 1059-1067. PMID: 39401325, PMCID: PMC11630746, DOI: 10.1093/oncolo/oyae259.Peer-Reviewed Original ResearchAdvanced colorectal cancerPIK3CA mutationsColorectal cancerPI3K inhibitionPI3K inhibitorsBurden of colorectal cancerActivating mutationsResponse to PI3K inhibitionSensitive to PI3K inhibition.Foundation Medicine databaseMetastatic colorectal cancerClinically relevant mutationsMicrosatellite instability-highPI3K signalingTumor DNAPIK3CA variantsClinical carePIK3CA oncogeneClinical variablesE545KGenomic profilingPIK3CAE542KMedicine DatabasePatientsDeep-Transfer-Learning–Based Natural Language Processing of Serial Free-Text Computed Tomography Reports for Predicting Survival of Patients With Pancreatic Cancer
Kim S, Kim S, Kim E, Cecchini M, Park M, Choi J, Kim S, Hwang H, Kang C, Choi H, Shin S, Kang J, Lee C. Deep-Transfer-Learning–Based Natural Language Processing of Serial Free-Text Computed Tomography Reports for Predicting Survival of Patients With Pancreatic Cancer. JCO Clinical Cancer Informatics 2024, 8: e2400021. PMID: 39151114, DOI: 10.1200/cci.24.00021.Peer-Reviewed Original ResearchConceptsArea under the receiver operating characteristic curveSurvival of patientsCT reportsPancreatic cancerNatural language processingC-indexPredicting survivalOverall survival of patientsTertiary hospitalPredicting 1-year survivalPredicting survival of patientsImproved C-indexSurvival informationPancreatic cancer survivalReceiver operating characteristic curveInternal test data setNLP modelsComputed tomography reportsLanguage processingKorean tertiary hospitalOverall survivalConsecutive patientsActual survivalConcordance indexPatientsPerioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer
Cecchini M, Salem R, Robert M, Czerniak S, Blaha O, Zelterman D, Rajaei M, Townsend J, Cai G, Chowdhury S, Yugawa D, Tseng R, Arbelaez C, Jiao J, Shroyer K, Thumar J, Kortmansky J, Zaheer W, Fischbach N, Persico J, Stein S, Khan S, Cha C, Billingsley K, Kunstman J, Johung K, Wiess C, Muzumdar M, Spickard E, Aushev V, Laliotis G, Jurdi A, Liu M, Escobar-Hoyos L, Lacy J. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer. JAMA Oncology 2024, 10: 1027-1035. PMID: 38900452, PMCID: PMC11190830, DOI: 10.1001/jamaoncol.2024.1575.Peer-Reviewed Original ResearchProgression-free survivalPancreatic ductal adenocarcinomaOverall survivalCtDNA levelsPhase 2 nonrandomized controlled trialAnalysis of circulating tumor DNAMedian progression-free survivalResectable pancreatic ductal adenocarcinomaControlled trialsAssess surgical candidacyBaseline ctDNA levelModified 5-fluorouracilResectable pancreatic cancerPancreatic protocol computed tomographyAssociated with recurrenceTumor molecular featuresAggressive malignant tumorKaplan-Meier estimatesRandomized clinical trialsStandard of careCtDNA-positivePreoperative cyclesNonrandomized controlled trialsUnresectable diseaseModified FOLFIRINOXAssociation of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma
Botta G, Abdelrahim M, Drengler R, Aushev V, Esmail A, Laliotis G, Brewer C, George G, Abbate S, Chandana S, Tejani M, Malla M, Bansal D, Rivero-Hinojosa S, Spickard E, McCormick N, Cecchini M, Lacy J, Fei N, Kasi P, Kasi A, Dayyani F, Hanna D, Sharma S, Malhotra M, Aleshin A, Liu M, Jurdi A. Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma. The Oncologist 2024, 29: 859-869. PMID: 39022993, PMCID: PMC11449101, DOI: 10.1093/oncolo/oyae155.Peer-Reviewed Original ResearchMolecular residual diseasePancreatic ductal adenocarcinomaPatient survival outcomesCtDNA detectionSurvival outcomesStage I–III pancreatic ductal adenocarcinomaAssociated with shorter DFSMedian follow-up timeFollow-up timeCtDNA levelsResidual diseaseShorter DFSPrognostic factorsPancreatic adenocarcinomaAssociated with patient survival outcomesDuctal adenocarcinomaRetrospective analysisDiagnosed patientsMultivariate analysisSurveillance periodPatientsPlasma samplesTumor informationWhole exomeSurveillance windowProofreading the way: immune checkpoint inhibitors in polymerase ε/polymerase δ (POLE/POLD1)-altered colorectal cancer
Cecchini M, Sundar R. Proofreading the way: immune checkpoint inhibitors in polymerase ε/polymerase δ (POLE/POLD1)-altered colorectal cancer. Annals Of Oncology 2024, 35: 582-584. PMID: 38910015, DOI: 10.1016/j.annonc.2024.04.006.Commentaries, Editorials and LettersInterim results of the randomized phase 2 cohort of study FW-2020-01 assessing the efficacy, safety and pharmacodynamics of CM24 in combination with nivolumab and chemotherapy in advanced/metastatic pancreatic cancer.
Macarulla T, Cecchini M, Garcia-Carbonero R, Golan T, Perets R, Borazanci E, Pedregal M, Ponz-Sarvise M, Al Hallak M, Pant S, Boni V, Saavedra O, de Miguel M, Leal A, Muñoz Martín A, Sauri T, Schickler M. Interim results of the randomized phase 2 cohort of study FW-2020-01 assessing the efficacy, safety and pharmacodynamics of CM24 in combination with nivolumab and chemotherapy in advanced/metastatic pancreatic cancer. Journal Of Clinical Oncology 2024, 42: lba4143-lba4143. DOI: 10.1200/jco.2024.42.17_suppl.lba4143.Peer-Reviewed Original ResearchDisease control rateProgression free survivalPancreatic ductal adenocarcinomaCarcinoembryonic antigen cell adhesion molecule 1Nal-IRIGemcitabine/nab-paclitaxelOverall survivalData cut-off dateRandomized phase 2 studyMedian follow-up timeCut-off dateAdequate organ functionAdvanced/metastatic pancreatic cancerPhase 2 studyLog-rank testFollow-up timeCell adhesion molecule 1Adhesion molecule 1Liposomal irinotecanFree survivalLine therapyOpen-labelSystemic therapyPFS-HRPrimary endpointA single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer
Verma N, Johung K, Kortmansky J, Zaheer W, Lacy J, Cecchini M, Stein S, Cheng Y, Lam W, Liu S, Reddy V, Hochster H, Higgins S. A single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer. Journal Of Gastrointestinal Oncology 2024, 15: 1050-1059. PMID: 38989411, PMCID: PMC11231844, DOI: 10.21037/jgo-24-23.Peer-Reviewed Original ResearchA phase I study of irinotecan combined with BAY1895344 (ATR inhibitor) in advanced solid tumors: Results of ETCTN 10402 dose escalation.
Heumann T, Stockton S, Cecchini M, Aljumaily R, Shyr C, Whisenant J, Starr J, Dayyani F, Baranda J, Trikalinos N, Ivy S, LoRusso P, Das S, Gore S, Beumer J, Berlin J. A phase I study of irinotecan combined with BAY1895344 (ATR inhibitor) in advanced solid tumors: Results of ETCTN 10402 dose escalation. Journal Of Clinical Oncology 2024, 42: 3077-3077. DOI: 10.1200/jco.2024.42.16_suppl.3077.Peer-Reviewed Original ResearchAdvanced solid tumorsMaximum tolerated doseDose escalationSolid tumorsPhase I study of irinotecanRecommended phase 2 doseRefractory advanced solid tumorsPhase 2 dosePhase I studyAnti-tumor activityBiweekly irinotecanInhibitor irinotecanIrinotecan exposureWeekly irinotecanTolerated doseDosing scheduleCancer xenograftsAdult patientsIrinotecanAssess safetyATR inhibitorsElimusertibSecondary objectivesDoseStandard careA phase I study of ATR inhibitor BAY1895344 (elimusertib) plus topotecan (ETCTN 10402): Results of dose escalation.
Stockton S, Shyr C, Cecchini M, Aljumaily R, Halfdanarson T, Sonbol M, Whisenant J, Ivy S, LoRusso P, Das S, Gore S, Berlin J, Beumer J, Heumann T. A phase I study of ATR inhibitor BAY1895344 (elimusertib) plus topotecan (ETCTN 10402): Results of dose escalation. Journal Of Clinical Oncology 2024, 42: 3076-3076. DOI: 10.1200/jco.2024.42.16_suppl.3076.Peer-Reviewed Original ResearchMaximum tolerated doseDose escalationDose levelsMedian progression-free survivalRecommended phase 2 doseRefractory advanced solid tumorsResults of dose escalationTreatment-related adverse eventsSmall cell lung cancerDisease control ratePhase 2 dosePhase Ia studyDose-limiting toxicityProgression-free survivalAdvanced solid tumorsPhase I studyCell lung cancerAnti-tumor activityExpansion cohortPartial responseTolerated doseTopotecan exposureStudy drugCancer xenograftsRespiratory failure
Clinical Trials
Current Trials
Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy
HIC ID2000033374RoleSub InvestigatorPrimary Completion Date07/31/2025Recruiting ParticipantsColon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
HIC ID2000032928RoleSub InvestigatorPrimary Completion Date03/10/2029Recruiting ParticipantsA Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE)
HIC ID2000032119RoleSub InvestigatorPrimary Completion Date03/17/2026Recruiting ParticipantsOpen Label, Multicenter, Phase 1 Study to Evaluate the Maximum Tolerated Dose of Orally Administered CB-03-10 With Dose Expansion Phase, in Subjects With Advanced Solid Tumors
HIC ID2000032542RoleSub InvestigatorPrimary Completion Date01/01/2026Recruiting ParticipantsA Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation
HIC ID2000032188RoleSub InvestigatorPrimary Completion Date10/31/2026Recruiting Participants
Academic Achievements & Community Involvement
Clinical Care
Overview
Michael Cecchini, MD, is a medical oncologist who specializes in gastrointestinal cancers, including (but not limited to) colorectal, bile duct, pancreas, esophageal, and stomach cancers. He often cares for patients with advanced gastrointestinal cancers and is an investigator in multiple research trials to help them get treatments that are not always available elsewhere.
“Taking care of patients and spending the time to get to know them is the best part of my job,” Dr. Cecchini says. It helps to draw upon the diverse expertise of colleagues at Smilow and those in non-cancer specialties, he adds. “At Yale we have an excellent multidisciplinary team that will work hard to treat your cancer, manage your symptoms, and deliver the care you deserve as a patient.”
Dr. Cecchini was inspired to become a cancer specialist partly because he wanted to have opportunities to perform research to improve options for his patients. “Few specialties are so integrated with close patient relationships and translational research that can dramatically improve the lives of our patients and minimize side effects,” he says. His translational research includes clinical and lab projects to study DNA damage and the immune response, primarily for colorectal cancer. He is the recipient of a Young Investigator Award from the Conquer Cancer Foundation for research focused on metastatic gastric cancer and 2020 Scholar on the Yale Cancer Center K12 Calabresi Immuno-Oncology Training Program.
Clinical Specialties
Gastrointestinal Oncology
Fact Sheets
Gastrointestinal Cancers
Learn More on Yale MedicineColorectal Cancer
Learn More on Yale MedicineSmall Intestine Adenocarcinoma
Learn More on Yale MedicineHyperthermic Intraperitoneal Chemotherapy (HIPEC)
Learn More on Yale Medicine
Board Certifications
Medical Oncology
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2018
Hematology (Internal Medicine)
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2018
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2015
Yale Medicine News
News & Links
News
- February 26, 2025
Celebrating Yale Cancer Center Faculty, Research Scientists
- December 16, 2024Source: Yahoo Canada
This Is One Unexpected Sign Of Colon Cancer That Doctors Urge People Not To Ignore
- November 08, 2024Source: CURE
James Van Der Beek Has Colorectal Cancer, a Disease on the Rise in Younger Adults
- September 25, 2024Source: New York Post
I'm a doctor - these are the 6 common symptoms of colon cancer in young people
Get In Touch
Contacts
Appointment Number
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
Events
Mar 202527Thursday
- EveryoneMichael Cecchini, MD - Jacquelyne Gaddy, MD, MSc, MSCR - Haddon Pantel, MDWe will meet on Zoom.